2021 Revenues ($USD) : $22,959,000,000
2021 R&D spend : $2,174,000,000
2021 Number of Employees : not available
Fiscal Year End : 1/3/2021
Key People : Alex Gorsky, chairperson, board of directors and CEO; Joaquin Duato, vice chairperson, executive committee; Peter Fasolo, EVP, chief human resources officer; Ashley McEvoy, EVP, worldwide chairperson, medical devices; Thibaut Mongon, EVP, worldwide chairperson, consumer health; Michael Sneed, EVP, global corporate affairs and chief communication officer; Paul Stoffels, vice chairperson, executive committee and chief scientific officer; Jennifer Taubert, EVP, worldwide chairperson, pharmaceuticals; Michael Ullmann, EVP, general counsel; Kathy Wengel, EVP and chief global supply chain officer; Joseph J. Wolk, EVP, CFO.

About the company: The New Jersey–based conglomerate has a host of subsidiaries serving various medical device segments: DePuy Synthes for orthopedic devices; Ethicon for surgical technologies; Acclarent for ear, nose and throat (ENT) treatments; Biosense Webster for electrophysiology tools; Cerenovus for stroke treatment technologies; Mentor for breast implants; Sterilmed for reprocessed single-use devices; and Johnson & Johnson Vision for eye protection and treatment products. Overall, 2021 appears to have been a year of ongoing recovery for J&J’s medical device business. It’s also a time of transition as CEO Alex Gorsky prepares to end a decade of leadership at the company, turning over the reins to J&J veteran Joaquin Duato in the new year. Big wins this year included the FDA clearance and U.S. launch of the Velys robot-assisted knee replacement system. Meanwhile, the company reported a two-year delay in the development timeline for its Ottava general surgery robot, the company’s answer to Intuitive and its da Vinci robots. –CN